Intravitreal aflibercept injection in diabetic macular edema patients with and without prior anti-vascular endothelial growth factor treatment outcomes from the phase 3 program

Ophthalmology

Volumn 123, Issue 4, 2016, Pages 850-857

  Do, Diana V ^a   Nguyen, Quan Dong ^a   Vitti, Robert ^b   Berliner, Alyson J ^b   Gibson, Andrea ^b   Saroj, Namrata ^b   Soo, Yuhwen ^b   Boyer, David S ^c  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b REGENERON PHARMACEUTICALS INC   (United States)

^c RETINA VITREOUS ASSOCIATES MEDICAL GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN; VASCULOTROPIN A; VASCULOTROPIN RECEPTOR; VEGFA PROTEIN, HUMAN;

ADULT; ARTERIAL THROMBOEMBOLISM; ARTICLE; CATARACT; CENTRAL RETINAL THICKNESS; CONJUNCTIVAL HEMORRHAGE; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DOUBLE BLIND PROCEDURE; EXPLORATORY RESEARCH; EYE PAIN; FEMALE; HUMAN; LASER COAGULATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; OPHTHALMIC LASER; OUTCOME ASSESSMENT; PHASE 3 CLINICAL TRIAL; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RETINA HEMORRHAGE; TREATMENT DURATION; VISION; VISUAL ACUITY; VITREOUS BODY DETACHMENT; VITREOUS FLOATERS; VITREOUS HEMORRHAGE; AGED; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DRUG EFFECTS; INTRAVITREAL DRUG ADMINISTRATION; MACULAR EDEMA; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

AGED; ANGIOGENESIS INHIBITORS; DIABETIC RETINOPATHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; LASER COAGULATION; MACULAR EDEMA; MALE; MIDDLE AGED; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84961841563     PISSN: 01616420     EISSN: 15494713     Source Type: Journal    
DOI: 10.1016/j.ophtha.2015.11.008     Document Type: Article

References (20)

1. T.A. Ciulla, A.G. Amador, and B. Zinman Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies Diabetes Care 26 2003 2653 2664
2. R. Varma, N.M. Bressler, Q.V. Doan, and et al. Prevalence of and risk factors for diabetic macular edema in the United States JAMA Ophthalmol 132 2014 1334 1340
3. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1 Arch Ophthalmol 103 1985 1796 1806
4. T.A. Ciulla, A. Harris, N. McIntyre, and C. Jonescu-Cuypers Treatment of diabetic macular edema with sustained-release glucocorticoids: intravitreal triamcinolone acetonide, dexamethasone implant, and fluocinolone acetonide implant Expert Opin Pharmacother 15 2014 953 959
5. L.P. Aiello Angiogenic pathways in diabetic retinopathy N Engl J Med 353 2005 839 841
6. R. Simo, J.M. Sundstrom, and D.A. Antonetti Ocular Anti-VEGF therapy for diabetic retinopathy: the role of VEGF in the pathogenesis of diabetic retinopathy Diabetes Care 37 2014 893 899
7. Diabetic Retinopathy Clinical Research Network, M.J. Elman, H. Qin, and et al. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three-year randomized trial results Ophthalmology 119 2012 2312 2318
8. P. Mitchell, F. Bandello, U. Schmidt-Erfurth, and et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema Ophthalmology 118 2011 615 625
9. Q.D. Nguyen, D.M. Brown, D.M. Marcus, and et al. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE Ophthalmology 119 2012 789 801
10. U. Schmidt-Erfurth, G.E. Lang, F.G. Holz, and et al. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study Ophthalmology 121 2014 1045 1053
11. K. Kriechbaum, S. Prager, G. Mylonas, and et al. Intravitreal bevacizumab (Avastin) versus triamcinolone (Volon A) for treatment of diabetic macular edema: one-year results Eye (Lond) 28 2014 9 15
12. R. Rajendram, S. Fraser-Bell, A. Kaines, and et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data: report 3 Arch Ophthalmol 130 2012 972 979
13. D.V. Do, Q.D. Nguyen, D. Boyer, and et al. One-year outcomes of the DA VINCI study of VEGF Trap-Eye in eyes with diabetic macular edema Ophthalmology 119 2012 1658 1665
14. D.V. Do, U. Schmidt-Erfurth, V.H. Gonzalez, and et al. The DA VINCI study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema Ophthalmology 118 2011 1819 1826
15. J.F. Korobelnik, D.V. Do, U. Schmidt-Erfurth, and et al. Intravitreal aflibercept for diabetic macular edema Ophthalmology 121 2014 2247 2254
16. D.M. Brown, U. Schmidt-Erfurth, D.V. Do, and et al. Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies Ophthalmology 122 2015 2044 2052
17. N. Papadopoulos, J. Martin, Q. Ruan, and et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab Angiogenesis 15 2012 171 185
18. J.A. Wells, A.R. Glassman, A.R. Ayala, and et al. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema N Engl J Med 372 2015 1193 1203
19. M. Michaelides, A. Kaines, R.D. Hamilton, and et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2 Ophthalmology 117 2010 1078 1086 e2
20. Early Treatment Diabetic Retinopathy Study Research Group Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report number 12 Ophthalmology 98 1991 823 833